OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress

MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) ("OPKO") and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that their abstract "First-in- Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome" has been selected for a poster presentation at the 47 European Society for Clinical Nutrition & Metabolism ("ESPEN") Congress, taking place September 13–16, 2025, in Prague, Czech Republic. About OPKO Health OPKO Health is a multinational biopharmaceutical and ...